Coherus gains on PK/PD readout for Neulasta biosimilar

Coherus BioSciences Inc. (NASDAQ:CHRS) gained $4.71 (27%) to $21.93 on Monday after it said CHS-1701

Read the full 154 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE